Moderna stock has delivered a strong 98.6% return over the past year, yet its broader valuation checks still lean expensive, so investors are weighing a sharp share price recovery against signals that the current price may already reflect a lot of optimism.

• Moderna is up 98.6% over the last 12 months, which puts recent buyers in a strong position but raises the bar for any further upside to be justified by fundamentals.
• Expectations around the company’s vaccine pipeline and cost discipline can support the current share price, while uncertainty around setbacks such as the norovirus program may limit how much investors are willing to pay for that future potential.
• On Simply Wall St’s valuation checks, Moderna scores 1 out of 6, which suggests the stock is not a clear bargain on the broader measures being applied.

The issue now is whether Moderna’s recent share price strength leaves enough room for long term investors to be comfortable with the current valuation.

Has Moderna Run Too Far on Sales?

P/S is often the cleaner lens for Moderna because the company is still reporting losses and the usual P/E yardstick does not apply in a straightforward way. On this measure, Moderna trades on a P/S of about 9.8x, which is below the biotech industry average of 10.5x but well above the peer group average of roughly 5.3x.

The tailored fair P/S ratio from Simply Wall St’s model sits closer to 3.0x. The gap is very wide, and the model is heavily penalising Moderna’s recent losses, risk profile and dependence on a relatively narrow set of commercial products, so that 3.0x figure is better read as a warning flag than as a precise target. Despite the recent Q2 earnings beat and improved cost outlook, the current P/S still prices Moderna at a rich level compared with what this framework suggests for its fundamentals.

On the preferred P/S multiple, Moderna stock screens as overvalued even after allowing for its revenue profile and industry positioning.

The Moderna Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Moderna leaves off. They set out the specific paths for Moderna's revenue, margins and earnings that would need to play out for the stock to be worth meaningfully more or less than it is today, based on the scenarios shared on the Community page. Where a single ratio or model gives one figure, Narratives describe the future that figure relies on so you can monitor whether it still lines up with reality.

Community views on Moderna sit far apart, with one camp focused on platform upside and the other warning that expectations are already stretching the story.

Bull case: 17% undervalued

"The deployment of advanced AI and digital automation across all functions is transforming R&D, manufacturing, and commercial processes, with ongoing improvements sharply reducing development timelines and operational costs..."

Bear case: 24% overvalued

"Sustained decline in COVID-19 vaccine revenues and continued seasonality in the respiratory vaccine portfolio expose Moderna to ongoing revenue volatility, with pipeline diversification and non-seasonal products not yet adequately compensating for this downturn..."

Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!

The Bottom Line

Moderna now screens as overvalued on the market multiples that matter most, with the tailored P/S framework flagging a wide gap between the current tag and what its recent losses and risk profile would usually support. The low broader valuation score underlines that this is not a simple quality at a discount story. From here, the key question is whether Moderna can broaden and stabilise its revenue base in a way that convinces investors the current rich multiple is justified rather than a setup for a reset.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.